Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Solitary Fibrous Tumors × eribulin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 108 Triple Negative Breast Neoplasms 24 Neoplasm Metastasis 17 Sarcoma 15 Neoplasms 15 Ovarian Neoplasms 5 Carcinoma, Non-Small-Cell Lung 5 Brain Neoplasms 5 Prostatic Neoplasms 4 Urinary Bladder Neoplasms 3 Unspecified Adult Solid Tumor, Protocol Specific 3 Liposarcoma 3 Inflammatory Breast Neoplasms 3 Carcinoma, Transitional Cell 3 Urethral Neoplasms 2 Ureteral Neoplasms 2 Sarcoma, Ewing 2 Rhabdomyosarcoma 2 Recurrence 2 Pancreatic Neoplasms 2 Lymphoma 2 Leiomyosarcoma 2 HER2-negative Breast Cancer 2 Colorectal Neoplasms 2 Carcinoma 2 Advanced Breast Cancer 2 Uterine Cervical Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solitary Fibrous Tumors 1 Salivary Gland Neoplasms 1

Interventions

Doxorubicin 3 pazopanib 2 Trabectedin 2 Ifosfamide 2 Dacarbazine 2 selinexor 1 repotrectinib 1 pembrolizumab 1 eribulin 1 Suspensions 1 Sunitinib 1 Proton Therapy 1 Nivolumab 1 Methotrexate 1 Magnetic Resonance Spectroscopy 1 Histamine H2 Antagonists 1 Fluorodeoxyglucose F18 1 Famotidine 1 FAPI-46 1 Epirubicin 1 Dasatinib 1 Cisplatin 1 Capsules 1 Axitinib 1 Angptl4 protein, mouse 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03840772 2024-09-20

ERASING

Italian Sarcoma Group

Phase 2 Completed

Sarcoma, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡